Correlation Between BioNTech and CITIUS PHARMAC

Can any of the company-specific risk be diversified away by investing in both BioNTech and CITIUS PHARMAC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BioNTech and CITIUS PHARMAC into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between BioNTech SE and CITIUS PHARMAC DL, you can compare the effects of market volatilities on BioNTech and CITIUS PHARMAC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioNTech with a short position of CITIUS PHARMAC. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioNTech and CITIUS PHARMAC.

Diversification Opportunities for BioNTech and CITIUS PHARMAC

-0.37

Correlation Coefficient

BioNTech  CITIUS PHARMAC

Very good diversification

The 3 months correlation between BioNTech and CITIUS is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding BioNTech SE and CITIUS PHARMAC DL in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CITIUS PHARMAC DL and BioNTech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BioNTech SE are associated (or correlated) with CITIUS PHARMAC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CITIUS PHARMAC DL has no effect on the direction of BioNTech i.e., BioNTech and CITIUS PHARMAC go up and down completely randomly.

Pair Corralation between BioNTech and CITIUS PHARMAC

Assuming the 90 days trading horizon BioNTech SE is expected to generate 0.31 times more return on investment than CITIUS PHARMAC. However, BioNTech SE is 3.24 times less risky than CITIUS PHARMAC. It trades about 0.31 of its potential returns per unit of risk. CITIUS PHARMAC DL is currently generating about -0.33 per unit of risk. If you would invest  9,550  in BioNTech SE on September 16, 2024 and sell it today you would earn a total of  2,090  from holding BioNTech SE or generate 21.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	95.45%
Values	Daily Returns

BioNTech SE  vs.  CITIUS PHARMAC DL

BioNTech SE

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BioNTech may actually be approaching a critical reversion point that can send shares even higher in January 2025.

CITIUS PHARMAC DL

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CITIUS PHARMAC DL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with BioNTech and CITIUS PHARMAC

The main advantage of trading using opposite BioNTech and CITIUS PHARMAC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioNTech position performs unexpectedly, CITIUS PHARMAC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CITIUS PHARMAC will offset losses from the drop in CITIUS PHARMAC's long position.

The idea behind BioNTech SE and CITIUS PHARMAC DL pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.